NORTHBROOK, Ill., March 26, 2024 /PRNewswire/ -- Iveric Bio, An Astellas Company (TSE: 4503, President and CEO: Naoki Okamura, "Astellas"), today announced the U.S. Centers for Medicare and Medicaid ...

RAMSEY, N.J. and BOCA RATON, Fla., Jan. 26, 2021 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER) today announced that the U.S. Centers for Medicare & Medicaid Services (CMS) has assigned a permanent Healthcare Common Procedure Coding ...

BOSTON--(BUSINESS WIRE)--Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology announced today that a permanent J-code, J1449, has been ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Please provide your email address to receive an email when new articles are posted on . Several CMS-designated permanent and product-specific J-codes recently went into effect, allowing three ...

One of the fastest-growing healthcare expenditures today is medical drug costs: the 10 most expensive drugs in the U.S. cost between $600,000 to more than $2.1 million annually. Within that world of ...

If you’re preparing for the CBCS certification this year, the rules have changed under your feet. As of late 2024, the exam no longer permits physical coding manuals, forcing candidates to rely on ...

Please provide your email address to receive an email when new articles are posted on . Ycanth has received a permanent J-code for the treatment of molluscum contagiosum. The code will be fully ...

Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, ...